MDT · News · 20261020N

Regulatory Approval Milestones

Medtronic plc · 2026-10-20 · Importance 38 · Surprise 60 · In source text

Medtronic received a European CE mark for its Vitalis portfolio of five next-generation cardiac pacemakers, enabling sales across Europe. The devices use conduction system pacing to stimulate the heart’s natural electrical pathways and provide a more physiological alternative to conventional pacing. The portfolio includes ReSyncra CSP for cardiac resynchronization therapy and remote-monitoring capabilities intended to personalize treatment and simplify physician workflows.

Key facts

• Medtronic has received a CE mark for its Vitalis portfolio of cardiac pacemakers, enabling sales in Europe. source
• Medtronic's Vitalis portfolio CE clearance builds on Medtronic's earlier FDA approval for pacing the heart's natural conduction system. source
• The Vitalis next-generation pacemaker portfolio includes remote monitoring capabilities. source
• The Vitalis portfolio includes ReSyncra CSP as the most advanced device for patients needing cardiac resynchronization therapy. source
• The Vitalis portfolio includes five devices. source
• The Vitalis pacemakers offer conduction system pacing (CSP) therapy described as a more physiologic pacing option. source

Impact estimates